Having a sell sentiment because we are still waiting on data is...

Having a sell sentiment because we are still waiting on data is a bizarre stance IMHO. Like others I see this as an excellent announcement, for more than one reason. Aside from the suggestion that this could vastly improve our ability to treat hard to reach tumours, it may even improve efficacy across the board with all tumours. Furthermore, this is excellent advertising for us given that we are collaborating with another hot NASDAQ listing... that probably has a lot of investors who have never heard of IMU and aren't put off by the risky nature of biotechnology investing.

Any investor who thinks a biotech stock is a sell while waiting on data is probably not a great fit for this space. Each to their own of course.